Skip to main content
Fig. 1 | Breast Cancer Research

Fig. 1

From: Comparison of three scoring methods using the FDA-approved 22C3 immunohistochemistry assay to evaluate PD-L1 expression in breast cancer and their association with clinicopathologic factors

Fig. 1

Comparison of three scoring methods in the entire cohort and in the triple-negative breast cancer patients. a, b Summary of staining results by invasive tumor cells and tumor-infiltrating immune cells (TCIC), tumor-infiltrating immune cells only (IC), and invasive tumor cells (TC) in the entire cohort. c, d Summary of staining results by TCIC, IC, and TC in the triple-negative breast cancer patients. The darker color on the left of each row of b and d represents positive cases and the lighter color on the right negative cases

Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us